Treatment for Akathisia
For antipsychotic-induced akathisia, first attempt dose reduction of the offending antipsychotic, then consider switching to quetiapine or olanzapine; if medication adjustment is not feasible, add propranolol (10-30 mg two to three times daily) as first-line adjunctive therapy.
Algorithmic Treatment Approach
Step 1: Modify the Causative Antipsychotic
The most recent international guidelines 1 and APA guidelines 2 consistently recommend starting with antipsychotic modification:
- Dose reduction: Lower the antipsychotic dose while maintaining therapeutic efficacy 1, 2
- Switch antipsychotics: Consider switching to agents with lower akathisia liability, specifically quetiapine or olanzapine 1, 2
This approach directly addresses the root cause and often resolves akathisia without adding additional medications. The 2025 INTEGRATE guidelines specifically identify quetiapine and olanzapine as preferred alternatives due to their lower propensity to cause akathisia 1.
Step 2: Add Adjunctive Pharmacotherapy (if Step 1 is not feasible)
When antipsychotic modification cannot be done—for example, when psychotic symptoms are well-controlled and dose reduction risks relapse—proceed to adjunctive treatment.
First-Line Adjunctive Agent: Propranolol
- Dose: 10 mg up to 30 mg, two to three times daily 1
- Evidence strength: Supported by APA guidelines (2C level) 2 and confirmed effective in network meta-analyses 3, 4
- Mechanism: Beta-adrenergic blockade addresses the noradrenergic imbalance in akathisia 5
Alternative First-Line Options:
The APA guidelines suggest multiple options with similar evidence levels (all 2C) 2:
- Benzodiazepines (e.g., clonazepam): Particularly useful when anxiety accompanies akathisia
- Switching to another antipsychotic: As noted above
Step 3: Consider Additional Evidence-Based Alternatives
Recent high-quality network meta-analyses 3, 4 from 2024 provide updated evidence on alternative agents:
Highly Effective Options (based on 2024 meta-analysis):
- Mirtazapine 15 mg/day: Strongest effect size (SMD -1.20) among all agents studied 3, with recent case reports confirming efficacy in treatment-resistant cases 6
- Vitamin B6 600-1200 mg/day: Excellent efficacy-to-tolerability profile 3, 4
- Biperiden 6 mg/day (anticholinergic): Strong efficacy (SMD -1.01) 3
Moderately Effective Options:
Important Clinical Considerations
Common Pitfalls to Avoid
Misdiagnosis: Akathisia can be mistaken for anxiety, agitation, or worsening psychosis. Use a validated scale (Barnes Akathisia Rating Scale) to confirm diagnosis 7
Overlooking high-risk antipsychotics: Even "atypical" antipsychotics like aripiprazole and cariprazine can cause significant akathisia despite causing few other extrapyramidal symptoms 5
Propranolol contraindications: Screen for asthma, bradycardia, and hypotension before prescribing beta-blockers
Duration of adjunctive therapy: The evidence for long-term use of adjunctive medications is limited 7. Reassess regularly and attempt to taper if akathisia resolves
Divergent Evidence
While the 2020 APA guidelines 2 list propranolol, benzodiazepines, and antipsychotic switching as equivalent options (all 2C level), the 2025 INTEGRATE guidelines 1 specifically prioritize propranolol as the adjunctive medication of choice. The 2024 network meta-analyses 3, 4 suggest that 5-HT2A antagonists (mirtazapine, trazodone, mianserin) may have superior efficacy, though confidence in this evidence remains low to very low.
Practical synthesis: Start with propranolol given its established guideline support and safety profile. Reserve mirtazapine for treatment-resistant cases or when comorbid depression/insomnia exists, as demonstrated in recent case reports 6.
Chronic/Tardive Akathisia
For persistent akathisia that continues after antipsychotic discontinuation, pharmacological management becomes more challenging 5. Consider rotating between different medication classes (beta-blockers → mirtazapine → benzodiazepines → gabapentinoids) if initial treatments fail 5.
Monitoring
Systematically assess akathisia severity using a validated scale (Barnes Akathisia Rating Scale) before starting antipsychotics and during dose titration 7. This allows objective tracking of treatment response.